Analysis of the clinical efficacy of eflornithine (IWILFIN) in the treatment of neuroblastoma

Eflornithine (IWILFIN) is a new type of oral fluoropyrimidine antimetabolite drug. It mainly inhibits the activity of thymidylate synthase (TS) and interferes with DNA synthesis and repair, thereby preventing tumor cell proliferation. The application of this drug in patients with neuroblastoma (Neuroblastoma, NB), especially for relapsed or refractory cases, shows important clinical potential. Eflornithine has strong targeting ability and can effectively inhibit rapidly dividing neuroblasts, thereby achieving precise intervention in tumors.

Clinical studies have shown that eflornithine can significantly extend progression-free survival (PFS) in patients with relapsed or refractory neuroblastoma. Some clinical trial data show that patients treated with eflornithine have reduced tumor burden and significantly improved tumor response rate (ORR). At the same time, the drug can improve the patient's quality of life, allowing them to maintain better daily activities while receiving treatment. For some high-risk pediatric patients, the combination regimen of eflornithine also shows good synergistic effects.

In terms of treatment course management, eflornithine generally needs to be used continuously for multiple cycles to observe the efficacy. Patients may experience mild to moderate gastrointestinal reactions, such as nausea, vomiting, or decreased appetite, during the initial treatment phase, but most symptoms can be relieved by adjusting the dosing method, using anti-nausea medications, or supportive care. Hematological toxicities such as mild anemia and neutropenia also require attention. Therefore, blood routine and liver and kidney functions need to be monitored regularly during medication so that timely intervention measures can be taken to ensure patient medication safety.

Overall, eflornithine has certain clinical advantages in the treatment of neuroblastoma, especially for relapsed or refractory patients. Eflornithine provides new treatment options for high-risk patients by slowing tumor progression, improving quality of life, and when combined with other chemotherapy regimens. However, since the drug has not yet been widely marketed globally, patients should receive treatment in professional hospitals or within the framework of clinical trials, with strict efficacy evaluation and safety monitoring to achieve maximum clinical benefit.

Reference link:https://www.drugs.com